Top in endocrinology: Once-weekly insulin, weight loss in type 2 diabetes

The efficacy of an investigational, once-weekly insulin therapy was similar to daily insulin glargine in patients with type 2 diabetes, according to data from a phase 2 trial. It was the top story in endocrinology last week.

Another top story was about research that showed weight loss can help restore pancreas function among people experiencing type 2 diabetes remission.

Read these and more top stories in endocrinology below:

Once-weekly insulin efficacy similar to daily therapy in type 2 diabetes

Adults with type 2 diabetes assigned to an investigational, once-weekly insulin therapy experienced a decrease in HbA1c similar to that seen with daily insulin glargine, according to findings from a phase 2 randomized controlled trial. Read more.

Weight loss may restore pancreas function in type 2 diabetes

Weight loss can help the pancreas return to its normal size and shape for people experiencing type 2 diabetes remission, according to a presenter at the European Association for the Study of Diabetes virtual meeting. Read more.

Later menarche associated with better cardiovascular health

Women who had menarche at a later age are more likely to have better cardiovascular health, according to a study published in Menopause. Read more.

‘We have more to learn’: Data inconclusive on COVID-19 driving form of type 1 diabetes

Reports of patients developing new-onset type 1 diabetes in the setting of COVID-19 infection have researchers questioning whether the virus is entering and subsequently destroying beta cells in pancreatic islets, according to a speaker. Read more.

Greater exercise capacity could mean longer life for adults with type 2 diabetes

Among people with type 2 diabetes, those with increased exercise capacity had a significantly decreased risk for all-cause mortality, according to data presented at the virtual European Association for the Study of Diabetes annual meeting. Read more.